Now, the drugmaker and co-defendants, including Pfizer, Sanofi, and Boehringer Ingelheim, have filed an ... to appeal directly to the higher court. Zantac was originated by GSK and launched ...

The complaints revolve around allegations that Zantac and other medicines containing ... which include Sanofi, Boehringer Ingelheim and Pfizer. In its latest statement, GSK reiterated its position ...

Within these costs we have included the likely payouts related to the increasingly concerning Zantac litagation ... for consumer products with Boehringer Ingelheim and the purchase of Bioverativ ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

GSK said total sales fell by two per cent in the third quarter Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and ...

GSK (GSK) used its third-quarter trading update to draw a definitive line under the damaging litigation around its now discontinued heartburn medicine Zantac, by agreeing a settlement earlier in ...

Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure sustainable patient access to Boehringer Ingelheim’s portfolio of leading ...

Operating profit fell by 86 per cent, and earnings per share slumped due to a settlement charge of £1.8bn related to the ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...

Scott + Scott and the Connecticut Attorney General's Office worked together to obtain a $39 million verdict against a Florida-based pharmacy that defrauded the state of $10 million in a kickback ...

Connecticut Attorney General William Tong announced two cooperation agreements and settlements with Heritage Pharmaceuticals and Apotex Corp., totaling $49.1 million, due to each companies ...